Fatal Varicella-Zoster Virus Vasculopathy Associated With Adalimumab Therapy | Cerebrovascular Disease | JAMA Neurology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.177.17. Please contact the publisher to request reinstatement.
Observation
Sep 2012

Fatal Varicella-Zoster Virus Vasculopathy Associated With Adalimumab Therapy

Author Affiliations

Author Affiliations: Department of Neurology, College of Medicine (Drs Baek, Lee, Y. S. Kim, and H. Y. Kim), and Hospital for Rheumatic Diseases (Drs J.-H. Kim and Jun), Hanyang University, Seoul, Republic of Korea.

Arch Neurol. 2012;69(9):1193-1196. doi:10.1001/archneurol.2011.3741
Abstract

Objective To describe the case of a patient who had been receiving adalimumab for rheumatoid arthritis and died of varicella-zoster virus vasculopathy with multifocal cerebral hemorrhage.

Design Case report.

Setting Hanyang University Hospital, Seoul, Republic of Korea.

Patient A 66-year-old woman with adalimumab therapy for rheumatoid arthritis followed by stuporous mental changes.

Results Magnetic resonance imaging scans showed multifocal parenchymal lesions and hemorrhage in the brainstem and supratentorial areas. Polymerase chain reaction analysis of the cerebrospinal fluid was positive for varicella-zoster virus. The patient died of multifocal vasculopathy despite intensive antiviral and antibacterial medication.

Conclusions Varicella-zoster virus multifocal vasculopathy with encephalitis may be associated with adalimumab therapy. Clinicians should be aware of the possibility of fatal varicella-zoster virus vasculopathy with encephalitis in patients undergoing adalimumab therapy for rheumatoid arthritis.

×